MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
50.10
+0.72
+1.46%
After Hours: 50.17 +0.07 +0.14% 19:59 12/01 EST
OPEN
49.40
PREV CLOSE
49.38
HIGH
50.18
LOW
48.93
VOLUME
12.81M
TURNOVER
0
52 WEEK HIGH
81.44
52 WEEK LOW
48.25
MARKET CAP
101.94B
P/E (TTM)
12.70
1D
5D
1M
3M
1Y
5Y
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 16h ago
5 Relatively Secure And Cheap Dividend Stocks To Invest In - December 2023
Home dividends analysis dividend strategy: 5 relatively secure and cheap dgi stocks to invest in - december 2023. We highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We select just five conservative dgi stocks from more than 7,500 companies traded on u.s. Exchanges.
Seeking Alpha · 1d ago
Bristol Myers Squibb new CEO buys company shares
Chris boerner, the new ceo of bristol myers squibb, purchased 3,071 company shares for $48.86 each. The $150k purchase boosted his stake by 4% to 79.4k shares. It appears to be his first insider buying at the pharma giant.
Seeking Alpha · 2d ago
Top Buys by Top Brass: Chief Executive Officer Boerner's $150K Bet on BMY
NASDAQ · 2d ago
Bristol Myers Squibb CEO Chris Boerner Buys Up Stock
Bristol myers ceo chris boerner paid $150,000 on nov. 28 for 3,071 shares of the drug company's stock. Bristol myers stock has lost about a third of its value so far this year. He now owns 79,384 shares in a personal account.
Barron‘s · 2d ago
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
NASDAQ · 2d ago
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
NASDAQ · 2d ago
Bristol Myers Stock Is Slumping. One Director Bought Up Shares.
Bristol myers squibb stock dropped to a multiyear low on nov. 20. The pharmaceutical company's lead independent director bought shares on the open market for the first time in years. Theodore r. Samuels paid $423,400 for 8,500 bristol myers shares.
Barron‘s · 3d ago
More
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.